论文部分内容阅读
目的:探讨加贝酯对内镜下逆行胰胆管造影术(ERCP)治疗胆总管结石的影响。方法:将2010年3月至2012年9月昆山市第一人民医院收治的86例拟行ERCP术的胆总管结石患者按随机双盲原则分为加贝酯组(46例)和对照组(40例)。统计两组ERCP选择性胆管插管成功率、术后高淀粉酶血症和术后胰腺炎发生率。结果:加贝酯组和对照组患者选择性胆管插管成功率、术后胰腺炎发生率分别为93%(43/46)和85%(34/40)、7%(3/46)和12%(5/加),两组比较,差异无统计学意义(P>0.05)。加贝酯组和对照组患者术后高淀粉酶血症发生率分别为17%(8/46)和38%(15/40),两组比较,差异有统计学意义(P<0.05)。结论:ERCP术前使用加贝酯不能提高胆总管结石ERCP选择性胆管插管成功率,也不能减少ERCP术后胰腺炎的发生,但可降低ERCP术后高淀粉酶血症的发生。
Objective: To investigate the effect of Gabapeptide on endoscopic retrograde cholangiopancreatography (ERCP) in the treatment of common bile duct stones. Methods: Eighty-six patients with choledocholithiasis admitted to First People’s Hospital of Kunshan from March 2010 to September 2012 were randomly divided into two groups according to the randomized double-blind principle: gabexate group (n = 46) and control group 40 cases). The success rate of ERCP selective bile duct intubation, postoperative hypermylase and postoperative pancreatitis were calculated. Results: The success rates of selective biliary intubation and postoperative pancreatitis were 93% (43/46) and 85% (34/40), 7% (3/46) and 12% (5 / plus), no significant difference between the two groups (P> 0.05). The incidence of hyper amylase in the gabexate group and the control group were 17% (8/46) and 38% (15/40), respectively. There was significant difference between the two groups (P <0.05). Conclusions: The use of gabexate premedication with ERCP can not improve the success rate of ERCP selective cholangiotracheal intubation in patients with common bile duct stones, nor can it reduce the incidence of pancreatitis after ERCP, but also reduce the incidence of hypermylase in ERCP patients.